NasdaqGS:BIIBBiotechs
Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point
Biogen (NasdaqGS:BIIB) reports strong commercial performance for Alzheimer’s treatment Leqembi, reflected in collaboration revenues and in market sales.
The US FDA grants Breakthrough Therapy Designation to litifilimab for cutaneous lupus erythematosus, marking a key step in Biogen’s immunology efforts.
Biogen announces promising clinical results for a high dose SPINRAZA regimen for spinal muscular atrophy, with regulatory review ongoing in the US and approvals already in the EU and...